PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739366
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739366
Sanger Sequencing
Global Sanger Sequencing Market to Reach US$8.9 Billion by 2030
The global market for Sanger Sequencing estimated at US$3.4 Billion in the year 2024, is expected to reach US$8.9 Billion by 2030, growing at a CAGR of 17.5% over the analysis period 2024-2030. Shotgun Sequencing, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Targeted Gene Sequencing segment is estimated at 19.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$894.2 Million While China is Forecast to Grow at 16.6% CAGR
The Sanger Sequencing market in the U.S. is estimated at US$894.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.9% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.0% CAGR.
Global "Sanger Sequencing" Market - Key Trends & Drivers Summarized
Why Does Sanger Sequencing Remain Relevant in a Genomics-Driven World?
Despite the rise of next-generation sequencing (NGS) platforms, Sanger sequencing retains its relevance due to its unparalleled accuracy, simplicity, and cost-effectiveness for specific applications. It remains the gold standard for sequence validation, single-gene diagnostics, and small-scale research projects. This method is highly valued in clinical genomics for confirming variants identified through high-throughput methods. Researchers favor Sanger sequencing for its ability to deliver long, high-fidelity reads, often up to 1000 base pairs, which are ideal for detecting insertions, deletions, or mutations in targeted regions. Diagnostic labs use it extensively for genetic testing in rare diseases and hereditary conditions. Sanger’s minimal data output also simplifies storage and analysis, especially in resource-limited settings. It offers the added advantage of faster turnaround times when compared to complex NGS workflows. As the genomics market diversifies into veterinary, agricultural, and microbiological fields, Sanger sequencing’s robustness makes it an essential complementary technology. Its adaptability to capillary electrophoresis systems and integration with existing lab infrastructure continues to support its application across both legacy and emerging use cases.
How Is Technology Enhancing the Precision and Accessibility of Sanger Sequencing?
Recent advancements are significantly refining the Sanger sequencing workflow, reducing costs and improving throughput. Automation in DNA extraction, PCR cleanup, and reaction preparation has minimized manual errors and increased sample handling efficiency. Improvements in dye-terminator chemistry and capillary electrophoresis systems have enhanced signal clarity, speed, and data resolution. Compact, benchtop sequencers now allow decentralized sequencing in smaller labs and clinics. Integration with cloud-based bioinformatics platforms has also made data analysis, interpretation, and reporting more accessible to non-specialists. AI tools are being used to detect low-frequency variants with greater confidence. Reagent miniaturization is helping reduce per-sample costs, and open-source labware is facilitating low-cost adoption in educational institutions. Barcode tagging of samples is enabling higher levels of multiplexing, increasing lab productivity. Furthermore, real-time monitoring tools are ensuring quality control at every stage. As a result, Sanger sequencing is no longer just a manual lab procedure; it is evolving into a semi-automated, intelligent platform that fits neatly into the broader genomics ecosystem.
In Which Fields Is the Demand for Sanger Sequencing Growing Most Rapidly?
Sanger sequencing is experiencing renewed demand in specific verticals where accuracy and confirmation are paramount. In clinical diagnostics, it's frequently used for confirmatory testing of germline mutations, especially in cancer predisposition and rare disease panels. Its role is expanding in pharmacogenomics, where precise genotyping is essential for tailored therapies. Agricultural genomics is another growing field, with Sanger used for crop genotyping, trait confirmation, and breeding programs. In microbiology, it is employed for pathogen identification, antibiotic resistance analysis, and plasmid verification. Veterinary medicine is increasingly adopting Sanger for genetic screening in pedigree animals and disease tracking. Forensic labs continue to use the method for mitochondrial DNA analysis due to its high-quality read output. Educational institutions also rely on Sanger systems for training students in sequencing fundamentals due to their reliability and ease of use. The rise in outsourcing of sequencing services to contract research organizations (CROs) is further supporting steady market demand. These sector-specific requirements highlight Sanger’s unique role as a foundational technology in modern genomics.
The Growth In The Sanger Sequencing Market Is Driven By Several Factors...
The expansion of the Sanger sequencing market is underpinned by a blend of enduring technological appeal and shifting industry needs. Demand for high-confidence confirmatory testing in clinical diagnostics is sustaining its usage, especially as companion diagnostics gain traction in precision medicine. The increasing number of research initiatives in academic and government institutions is also fueling market expansion. Cost-effectiveness and ease of setup are making Sanger the method of choice for low-throughput labs, especially in developing regions. The growing complexity of NGS datasets has led to increased reliance on Sanger sequencing for final validation. Regulatory agencies prefer Sanger data for approvals due to its proven reproducibility and accuracy. Continued investments in lab automation and benchtop sequencing devices are making the technology more scalable. Moreover, the market is benefiting from growing collaborations between hospitals, CROs, and molecular diagnostic companies. With applications ranging from infectious disease surveillance to plant breeding, Sanger sequencing is thriving as a complementary solution in the broader genomic toolkit.
SCOPE OF STUDY:
The report analyzes the Sanger Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Shotgun Sequencing, Targeted Gene Sequencing, Other Types); Application (Diagnostics, Personalized Medicine, Forensics, Other Applications); End-Use (Government Research Institutes, Diagnostic Labs, Pharma & Biotech Companies, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 42 Featured) -
- AAT Bioquest
- Azenta Life Sciences (GENEWIZ)
- BaseClear
- BGI Genomics
- Eurofins Genomics
- GenScript
- Illumina
- LGC Biosearch Technologies
- Macrogen
- MCLAB
- Microsynth AG
- Nucleics
- Psomagen
- QIAGEN
- Roche Applied Science
- SeqLab
- Source BioScience
- Synlab
- Thermo Fisher Scientific
- Zymo Research
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Sanger Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Continued Use in Targeted DNA Sequencing Applications Sustains Demand for Sanger Sequencing
- Clinical Diagnostics and Genetic Validation Workflows Strengthen Business Case for Precision Sequencing
- Pharma and Biotech R&D Activities Throw the Spotlight on Sangers Reliability in Mutation Detection
- Growing Preference for Low-Throughput, High-Accuracy Techniques in Niche Applications Drives Adoption
- Cost-Effectiveness in Academic and Clinical Labs Sustains Long-Term Relevance of Sanger Platforms
- Rising Prevalence of Genetic Disorders Accelerates Use in Confirmatory Testing
- Expansion of Outsourced Sequencing Services Creates New Demand from Research Institutions
- Next-Generation Sequencing Limitations in Long Homopolymer Regions Create Opportunities for Sanger
- Regulatory Compliance in Clinical Genomics Favors Established and Validated Technologies
- Integration with NGS Workflows for Hybrid Pipelines Expands Market Potential
- Low Entry Cost and Training Requirements Sustain Adoption in Emerging Markets and Universities
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Sanger Sequencing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World 6-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Shotgun Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 5: World 6-Year Perspective for Shotgun Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 6: World Recent Past, Current & Future Analysis for Targeted Gene Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 7: World 6-Year Perspective for Targeted Gene Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World 6-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 11: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World 6-Year Perspective for Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 16: World Recent Past, Current & Future Analysis for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 17: World 6-Year Perspective for Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 18: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 19: World 6-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World 6-Year Perspective for Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 22: World Recent Past, Current & Future Analysis for Forensics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 23: World 6-Year Perspective for Forensics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
- TABLE 24: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 25: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 26: USA Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: USA 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
- TABLE 28: USA Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 29: USA 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
- TABLE 30: USA Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 31: USA 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
- CANADA
- TABLE 32: Canada Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: Canada 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
- TABLE 34: Canada Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 35: Canada 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
- TABLE 36: Canada Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 37: Canada 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
- JAPAN
- Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 38: Japan Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Japan 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
- TABLE 40: Japan Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 41: Japan 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
- TABLE 42: Japan Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 43: Japan 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
- CHINA
- Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 44: China Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: China 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
- TABLE 46: China Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 47: China 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
- TABLE 48: China Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 49: China 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
- EUROPE
- Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 50: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 51: Europe 6-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
- TABLE 52: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 53: Europe 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
- TABLE 54: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 55: Europe 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Europe 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
- FRANCE
- Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 58: France Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 59: France 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
- TABLE 60: France Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 61: France 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
- TABLE 62: France Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: France 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
- GERMANY
- Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 64: Germany Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 65: Germany 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
- TABLE 66: Germany Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 67: Germany 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
- TABLE 68: Germany Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Germany 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
- ITALY
- TABLE 70: Italy Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 71: Italy 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
- TABLE 72: Italy Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 73: Italy 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
- TABLE 74: Italy Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Italy 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
- UNITED KINGDOM
- Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 76: UK Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 77: UK 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
- TABLE 78: UK Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 79: UK 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
- TABLE 80: UK Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: UK 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
- REST OF EUROPE
- TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 83: Rest of Europe 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
- TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 85: Rest of Europe 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
- TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Rest of Europe 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
- ASIA-PACIFIC
- Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 89: Asia-Pacific 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
- TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 91: Asia-Pacific 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
- TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Asia-Pacific 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
- REST OF WORLD
- TABLE 94: Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 95: Rest of World 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030
- TABLE 96: Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 97: Rest of World 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030
- TABLE 98: Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Rest of World 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030
IV. COMPETITION
